Anti-inflammatory agent 118

Anti-inflammatory agent 118 (compound I8) (10-40 μM; 24 h) shows low cytotoxicity in RAW264.7 cells, with no significant toxicity at 10 μM and moderate toxicity at higher concentrations up to 40 μM^[1].
Anti-inflammatory agent 118 (10 μM; 2 h pre-incubation, 24 h LPS stimulation) potently inhibits LPS-induced NO, TNF-α, and IL-6 production in RAW264.7 cells, with particularly strong inhibition of IL-6^[1].
Anti-inflammatory agent 118 (10 μM) releases moderate amounts of bioactive NO in RAW264.7 cells without LPS stimulation^[1].
Anti-inflammatory agent 118 (1.25-20 μM; 2 h pre-incubation, 24 h LPS stimulation for fluorescence assay, 18 h LPS stimulation for Western blotting) inhibits LPS-induced iNOS expression in RAW264.7 cells in a dose-dependent manner^[1].
Anti-inflammatory agent 118 (5-20 μM; 2 h pre-incubation, 18 h LPS stimulation) inhibits LPS-induced p65 phosphorylation in RAW264.7 cells in a dose-dependent manner, with the strongest effect at 20 μM, though lower concentrations are less potent than the positive control 1400W (HY-18730)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.